logistic reasons, patients could not be recruited
ITEM
Influence of the Angiotensin Receptor Blocker Telmisartan on the Red Blood Cell Function and the Microcirculatory Perfusion
Sponsor study identifier
Secondary identifiers
interventional
40
1 country
1
Study Start
December 2007
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
January 2009
Actual (reported)Study Completion
January 2009
Actual (reported)The hypothesis of the presented study is: Telmisartan induces an increase of eNOS activity in RBC resulting in an enhanced intravascular NO bioavailability, an ameliorated RBC deformability and a reduction of RBC and platelet aggregation. This could be a potential mechanism of the improvement of microcirculatory disorders, especially in patients with diabetes mellitus and arterial hypertension, treated with Telmisartan.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 2009
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
November 15, 2007
Actual (reported)November 16, 2007
Actual (reported)December 2007
Date type not reportedThis date has not been verified as actual or estimated.
January 2009
Actual (reported)January 2009
Actual (reported)Changes in Elongation-Index (EI) Method: To determine the elongation index (EI) we use the Laser assisted optical rotational cell analyzer (Lorrca).
after 30 days of treatment with study drug/control
Improvement of microcirculatory perfusion (using laser doppler measurement)
after 30 days treatment
Improvement of endothelial function (using ultrasound measurements during flow mediated dilation)
after 30 days treatment
Increase in the total blood born NO pool (using reductive gase phase chemiluminescence
after 30 days treatment
Decrease of RBC aggregation (using Laser assisted optical rotational cell analyzer (Lorrca)
after 30 days of treatment
treatment with 80 mg Telmisartan per day for 30 days
treatment with 20mg Telmisartan per day for 30 days
application of 80mg or 20mg Telmisartan per day for 30 days
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
University Hospital
Aachen, North Rhine-Westphalia, 52074, Germany
Malte Kelm, MD, Univ.Prof.
Department of Cardiology, Angiology, Pulmonary Diseases and cardiologic critical care
First Submitted
November 15, 2007
First Posted
November 16, 2007
Study Start
December 2007
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
January 2009
Actual (reported)Telmisartan in Haemodialysis Patients With Chronic Heart Failure
Contact the study team to confirm eligibility.
Study Completion
January 2009
Actual (reported)Last Updated
January 29, 2009
Record last verified: 2009-01
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: